Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORTIFRENCH
2024-513728-40-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastrointestinal cancer comparing Methylprednisolone flash dose with Placebo (2 arms). Primary endpoint: Postoperative major complications within 30 days. Planned start Jul 2024; status: authorised.
02
Drugs
methylprednisolone
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on 2024-513728-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513728-40-00.